Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses

被引:291
作者
Brunstrom, Mattias [1 ]
Carlberg, Bo [1 ]
机构
[1] Umea Univ, Dept Publ Hlth & Clin Med, Med, SE-90187 Umea, Sweden
来源
BMJ-BRITISH MEDICAL JOURNAL | 2016年 / 352卷
关键词
CONVERTING-ENZYME-INHIBITION; LEFT-VENTRICULAR DYSFUNCTION; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR MORBIDITY; MICROVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; RECURRENT STROKE; URINARY ALBUMIN; DOUBLE-BLIND;
D O I
10.1136/bmj.i717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess the effect of antihypertensive treatment on mortality and cardiovascular morbidity in people with diabetes mellitus, at different blood pressure levels. DESIGN Systematic review and meta-analyses of randomised controlled trials. DATA SOURCES CENTRAL, Medline, Embase, and BIOSIS were searched using highly sensitive search strategies. When data required according to the protocol were missing but trials were potentially eligible, we contacted researchers, pharmaceutical companies, and authorities. ELIGIBILITY CRITERIA Randomised controlled trials including 100 or more people with diabetes mellitus, treated for 12 months or more, comparing any antihypertensive agent against placebo, two agents against one, or different blood pressure targets. RESULTS 49 trials, including 73 738 participants, were included in the meta-analyses. Most of the participants had type 2 diabetes. If baseline systolic blood pressure was greater than 150 mm Hg, antihypertensive treatment reduced the risk of all cause mortality (relative risk 0.89, 95% confidence interval 0.80 to 0.99), cardiovascular mortality (0.75, 0.57 to 0.99), myocardial infarction (0.74, 0.63 to 0.87), stroke (0.77, 0.65 to 0.91), and end stage renal disease (0.82, 0.71 to 0.94). If baseline systolic blood pressure was 140-150 mm Hg, additional treatment reduced the risk of all cause mortality (0.87, 0.78 to 0.98), myocardial infarction (0.84, 0.76 to 0.93), and heart failure (0.80, 0.66 to 0.97). If baseline systolic blood pressure was less than 140 mm Hg, however, further treatment increased the risk of cardiovascular mortality (1.15, 1.00 to 1.32), with a tendency towards an increased risk of all cause mortality (1.05, 0.95 to 1.16). Metaregression analyses showed a worse treatment effect with lower baseline systolic blood pressures for cardiovascular mortality (1.15, 1.03 to 1.29 for each 10 mm Hg lower systolic blood pressure) and myocardial infarction (1.12, 1.03 to 1.22 for each 10 mm Hg lower systolic blood pressure). Patterns were similar for attained systolic blood pressure. CONCLUSIONS Antihypertensive treatment reduces the risk of mortality and cardiovascular morbidity in people with diabetes mellitus and a systolic blood pressure more than 140 mm Hg. If systolic blood pressure is less than 140 mm Hg, however, further treatment is associated with an increased risk of cardiovascular death, with no observed benefit.
引用
收藏
页数:10
相关论文
共 80 条
[41]  
Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]
[42]   2013 ESH/ESC Guidelines for themanagement of arterial hypertension The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC) [J].
Mancia, Giuseppe ;
Fagard, Robert ;
Narkiewicz, Krzysztof ;
Redon, Josep ;
Zanchetti, Alberto ;
Boehm, Michael ;
Christiaens, Thierry ;
Cifkova, Renata ;
De Backer, Guy ;
Dominiczak, Anna ;
Galderisi, Maurizio ;
Grobbee, Diederick E. ;
Jaarsma, Tiny ;
Kirchhof, Paulus ;
Kjeldsen, Sverre E. ;
Laurent, Stephane ;
Manolis, Athanasios J. ;
Nilsson, Peter M. ;
Ruilope, Luis Miguel ;
Schmieder, Roland E. ;
Sirnes, Per Anton ;
Sleight, Peter ;
Viigimaa, Margus ;
Waeber, Bernard ;
Zannad, Faiez ;
Redon, Josep ;
Dominiczak, Anna ;
Narkiewicz, Krzysztof ;
Nilsson, Peter M. ;
Burnier, Michel ;
Viigimaa, Margus ;
Ambrosioni, Ettore ;
Caufield, Mark ;
Coca, Antonio ;
Olsen, Michael Hecht ;
Schmieder, Roland E. ;
Tsioufis, Costas ;
van de Borne, Philippe ;
Zamorano, Jose Luis ;
Achenbach, Stephan ;
Baumgartner, Helmut ;
Bax, Jeroen J. ;
Bueno, Hector ;
Dean, Veronica ;
Deaton, Christi ;
Erol, Cetin ;
Fagard, Robert ;
Ferrari, Roberto ;
Fagard, David Hasdai ;
Hoes, Arno W. .
JOURNAL OF HYPERTENSION, 2013, 31 (07) :1281-1357
[44]   Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin:: randomised, double blind, placebo controlled trial (the DIABHYCAR study) [J].
Marre, M ;
Lievre, M ;
Chatellier, G ;
Mann, JFE ;
Passa, P ;
Ménard, J .
BRITISH MEDICAL JOURNAL, 2004, 328 (7438) :495-499
[45]   Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. [J].
Mauer, Michael ;
Zinman, Bernard ;
Gardiner, Robert ;
Suissa, Samy ;
Sinaiko, Alan ;
Strand, Trudy ;
Drummond, Keith ;
Donnelly, Sandra ;
Goodyer, Paul ;
Gubler, Marie Claire ;
Klein, Ronald .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (01) :40-51
[46]  
Messerli FH, 2009, J AM COLL CARDIOL, V54, P279, DOI [10.1016/j.jacc.2009.03.053, 10.1016/j.jacc.2009.05.073]
[47]   Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure the CAMELOT study: A randomized controlled trial [J].
Nissen, SE ;
Tuzcu, EM ;
Libby, P ;
Thompson, PD ;
Ghali, M ;
Garza, D ;
Berman, L ;
Shi, H ;
Buebendorf, E ;
Topol, EJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2217-2226
[48]   Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension results of a randomized controlled trial - Results of a randomized controlled trial [J].
O'Hare, JP ;
Bilous, R ;
Mitchell, T ;
O'Callaghan, CJ ;
Viberti, GC ;
Willoughby, R ;
Riley, J ;
Robinson, AM ;
Reckless, JP ;
Havard, F ;
Sampson, M ;
Lloyd, A ;
Williams, T ;
Vora, J ;
Chattington, P ;
Hampson, K ;
Ibrahim, H ;
Borthwick, L ;
Willoughby, R ;
Viberti, G ;
Russell, C ;
Barnes, D ;
Macklin, A ;
Murphy, E ;
Stephens, E ;
Vincent, J ;
Tindall, H ;
Simpson, H ;
Knowles, E ;
Cunningham, B ;
Simpson, E ;
Bilous, R ;
Bilous, M ;
Mitchell, T ;
O'Halloran, D ;
Nugent, S ;
Hadden, D ;
Fetherstone, M ;
McCarton, D ;
McGurk, C ;
Johnston, C ;
Burton, J ;
Harris, C ;
Hempstead, H ;
Baksi, A ;
Bartlett, J ;
Heaton, C ;
Brown, K ;
Arora, A ;
Burke, J .
DIABETES CARE, 2000, 23 (12) :1823-1829
[49]   Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly Valsartan in Elderly Isolated Systolic Hypertension Study [J].
Ogihara, Toshio ;
Saruta, Takao ;
Rakugi, Hiromi ;
Matsuoka, Hiroaki ;
Shimamoto, Kazuaki ;
Shimada, Kazuyuki ;
Imai, Yutaka ;
Kikuchi, Kenjiro ;
Ito, Sadayoshi ;
Eto, Tanenao ;
Kimura, Genjiro ;
Imaizumi, Tsutomu ;
Takishita, Shuichi ;
Ueshima, Hirotsugu .
HYPERTENSION, 2010, 56 (02) :196-202
[50]   Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes [J].
Parving, Hans-Henrik ;
Brenner, Barry M. ;
McMurray, John J. V. ;
de Zeeuw, Dick ;
Haffner, Steven M. ;
Solomon, Scott D. ;
Chaturvedi, Nish ;
Persson, Frederik ;
Desai, Akshay S. ;
Nicolaides, Maria ;
Richard, Alexia ;
Xiang, Zhihua ;
Brunel, Patrick ;
Pfeffer, Marc A. ;
Juncos, Luis ;
Orias, Marcelo ;
Kuschnir, Emilio ;
Rusculleda, Marcelo ;
Garcia, Sergio ;
Farias, Eduardo ;
Lema, Luis ;
Hominal, Miguel ;
Montana, Oscar ;
Sala, Jorgelina ;
Diaz, Monica ;
Piskorz, Daniel ;
Vita, Nestor ;
Litwak, Leon ;
Sinay, Isaac ;
Marin, Marcos ;
Massari, Pablo ;
Majul, Claudio ;
Aizemberg, D. ;
Azize, Guillermo Moises ;
Bartolacci, Ines ;
Reboredo, Ana ;
Vico, Marisa ;
Milesi, Ricardo ;
Sessa, Horacio ;
Wassermann, Alfredo ;
Margulis, Fernando ;
Zangroniz, Pedro ;
Watschinger, B. ;
Prager, R. ;
Toplak, H. ;
Paulweber, B. ;
Drexel, H. ;
Francesconi, C. ;
Foeger, B. ;
Mayer, G. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (23) :2204-2213